<u>La Renon</u>



with

Eiref-40

Pantoprazole Gastro Resistant Tablets 40 mg

Eiref-D

Pantoprazole Gastro Resistant 40 mg and Domperidone 30 mg Prolonged Release Capsules



Pantoprazole Gastro Resistant 40 mg and Domperidone 30 mg Prolonged Release Capsules

Background:

- Gastroesophageal reflux disease (GERD) is a public health problem having a significant impact on society because it leads to a huge economic burden and decreased quality of life. The pooled prevalence of GERD in the Indian population is 15.57%.
- PPIs alone and in combination with prokinetics provide the most effective control of gastric acidity and related symptoms like epigastric pain, heartburn and reflux and are the treatment of choice.

Clinical Evidence:

- 1. PHARMACOECONOMIC EVALUATION OF PANTOPRAZOLE AND PANTOPRAZOLE PLUS DOM-PERIDONE IN THE TREATMENT OF PATIENTS WITH GERD.¹
- No. of Patients: 80 patients suffering from GERD.
- Dosage: Pantoprazole (40 mg once daily) and Pantoprazole + Domperidone (40 mg+30 mg once daily)
- Duration: 2 weeks
- ❖ Result:

	FSS G scores	Pre- score	Post - score	Mean of Difference	95% Confidence Interval	T value	p-value
Pantoprazole (N=40)	Rs	7.75	1.92	5.850	4.511-7.189	8.84	<0.001
	Ds	7.45	2.10	5.350	4.282-6.418	10.13	<0.001
	Ts	15.23	3.90	11.33	9.713-12.940	14.21	<0.001
Pantoprazole + Domperidone (N=40)	Rs	9.95	3.18	6.775	5.468-8.082	10.49	<0.001
	Ds	8.50	3.35	6.150	4.952-7.348	10.39	<0.001
	Ts	18.45	5.52	12.93	10.971-14.880	13.34	<0.001

Fig: Results of the mean improvement of Frequency Scale for the Symptoms of GERD (FSSG) score in both groups after two week treatment.

Difference between pre and post score of each group compared with Students paired t-test. Significance at p<0.05

*RS: Reflux score; DS: Dysmotility score; TS: Total score

Conclusion:

Pantoprazole and pantoprazole with domperidone both provide the most effective control of gastric acidity and related symptoms.


2. PREVENTION OF EROSIVE OESOPHAGITIS RELAPSE WITH PANTOPRAZOLE. 3


No. of Patients: 349

Dosage : Pantoprazole 20 mg and 40 mg

Duration: 12 months

* Result:





Conclusion:

Pantoprazole 40 mg is the most effective regimen and consistent in maintaining erosive esophagitis healing with a good safety and tolerability profile.

Pantoprazole in Eiref-40 & Eiref-D Offers:

- Pantoprazole has a higher chemical stability at neutral and moderately acidic pH compared with other PPIs, which makes it less likely to become activated in moderately acidic compartments of the body.⁴
- Have a longer duration of action than other PPIs as it is the only PPI to bind both cysteine 813 and cysteine 882, the more distal residue of the proton pump.⁴
- Maintenance oral pantoprazole therapy up to 3 years at dosage of 40-120 mg B.D is effective and well tolerated in patients with Zollinger Ellison syndrome.⁵
- At a single dose of Pantoprazole 40 mg for up to 8 weeks, provides more rapid relief of symptoms and superior healing of erosive esophagitis than Nizatidine 150 mg b.d.⁶
- It has a low potential for metabolic interactions with cytochrome P450-dependent oxidase system.

Domperidone in Eiref-D Offers:

- Domperidone acts as an both antiemetic and an upper gastrointestinal tract prokinetic agent.
- Dopamine plays an important physiologic role in the regulation of gastric emptying by producing gastric relaxation and inhibiting gastric motility.
- Domperidone has been shown to reduce GI symptoms and hospitalizations from gastroparesis & enhance the quality of life.⁸





Pantoprazole Gastro Resistant 40 mg and Domperidone 30 mg Prolonged Release Capsules

Description:

Eiref-40 contains Pantoprazole 40 mg and is available as a gastro-resistant tablet.

Eiref-D is a combination of Pantoprazole 40 mg (gastro-resistant) & Domperidone (prolonged release) 30 mg and is avai able as a hard gelatin capsule.

Indication:

GERD | Peptic Ulcer | Hyperacidity

Mode of Action:

Pantoprazole

Pantoprazole exerts its stomach acid-suppressing effects by preventing the final step in gastric acid production by covalently binding to sulfhydryl groups of cysteine found on the (H+, K+)-ATPase enzyme at the secretory surface of the gastric parietal cell. This effect leads to the inhibition of both basal and stimulated gastric acid secretion irrespective of the stimulus.

Domperidone

- The action of domperidone is to inhibit dopamine receptors and enhance the action of acetylcholine in GI tract and increase peristaltic stimulants.
- Domperidone increases the movements or contractions of the stomach and bowel. It acts as an antiemetic and prokinetic agent through its effects on the chemoreceptor trigger zone and motor function of the stomach and small intestine.

Dosage:

The recommended dosage of Eiref-40 & Eiref-D is once a day or as prescribed by a registered medicinal professional.

Presentation:

Eiref-40 is available as a strip of 10 Tablets. **Eiref-D** is available as a strip of 10 Capsules.

REFERENCES:

- 1. Rucha Ulhas Puranik et al., Pharmacoeconomic Comparison Between Pan vs. Pan D
- https://doi.org/10.1007/s12664-020-01104-0
 Aliment Pharmacol Ther 2004; 20: 567–575.
- 4. Clinical and Experimental Gastroenterology 2010:3
- 5. Aliment Pharmacol Ther 23, 437–444
- 6. Aliment Pharmacol Ther 2002; 16: 2043–2052.
- 7. Clinical Interventions in Aging 2007:2(1)
- 8. The American journal of gastroenterology vol. 92,6 (1997): 976-80.

La Renon Healthcare Private Limited

207-208 Iscon Elegance, Circle P, Prahlad Nagar Cross Roads, S.G. Highway, Ahmedabad-380015, Gujarat, India. Phone: + 91-79-6616-8998, 2693-6656 | Fax: +91-79-6616-8998 E-mail: info@larenon.com | Web: www.larenon.com

